Predictive Factors of Violence in Prison

Predictive Factors of Violence in Prison, Retrospective Study in an French Incarcerated Male Population

Prison concentrates people with violent behavior and patients suffering from psychiatric disorders. Aggression are daily, the suicide rate is 5 to 10 times higher than the ordinary environment and current prevention devices have shown their limits.

That's why, in order to improve the violence's prevention in prison, the investigator propose to identify the predictive factors of violence by studying retrospectively the link between the psychiatric profile and commission of violence after being jailed.

Study Overview

• Status: Completed
• Conditions: Prisoner
• Intervention / Treatment: Other: penintetiary's incident reports collection

Detailed Description

From the 1st January to the 31 December 2012, every man incarcerated was screened thanks to the Mini International Neuropsychiatric Interview (MINI) to establish the presence of a current and/or past psychiatric diagnoses. In addition, collection of violent incidents based on penitentiary's reports (aggression, suicide, self-mutilation, intoxication, murder…) was conducted .

Then statistic analysis compared psychiatric characteristics of prisoners according to whether they commit violence or not within 12 months after being jailed, distinguish the authors of self and hetero aggressive violence. Those tests are completed with a cluster analysis to precise psychiatric from criminological profiles of dangerousness.

• Study Type: Observational
• Enrollment (Actual): 1200

Contacts and Locations

Study Locations

• France
  • Montpellier, France, 34295
    • Uhmontpellier

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

• Sampling Method: Probability Sample

Study Population

male incarcerated in a french prison

Description

Inclusion criteria:

- being jailed from 1st january 2012 to 31 dec 2012 in the Villeneuve Lès Maguelonne prison (Hérault, France)

Exclusion criteria:

- opposition form, unable to understand french, age under 18

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
violent event	physical assault	within the 12 month after incarceration
violent event	suicide attempt	within the 12 month after incarceration
violent event	intoxication	within the 12 month after incarceration
violent event	violent death	within the 12 month after incarceration
violent event	sexual assault	within the 12 month after incarceration
violent event	fire	within the 12 month after incarceration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
suicide attempt	according to the prison suicide attempt recording	within the 12 month after incarceration
physical assault	according to the prison suicide attempt recording	within the 12 month after incarceration

Collaborators and Investigators

• Sponsor: University Hospital, Montpellier
• Collaborators: Inserm U1061 : Neuropsychiatry
• Investigators: Study Director: Mathieu LACAMBRE, MD, University Hospital, Montpellier

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 1, 2015
• Primary Completion (ACTUAL): October 10, 2017
• Study Completion (ACTUAL): March 1, 2018

Study Registration Dates

• First Submitted: October 10, 2017
• First Submitted That Met QC Criteria: November 13, 2017
• First Posted (ACTUAL): November 14, 2017

Study Record Updates

• Last Update Posted (ACTUAL): May 7, 2018
• Last Update Submitted That Met QC Criteria: May 4, 2018
• Last Verified: October 1, 2017

More Information

Terms related to this study

• Keywords: prevention; violence; predictive factors; jail
• Other Study ID Numbers: RECHMPL17_0324

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: NC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No